ALX Oncology (ALXO) Downgraded by Zacks Investment Research to Hold

ALX Oncology stock has undergone multiple analysts rating changes in the recent past.  ALX Oncology Downgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

Shares of ALX Oncology traded down -$0.56 on Wednesday, reaching $58.99. 78835 shares of the stock traded hands, compared to its average volume of 183390. Shares of ALX Oncology were trading at $58.99 on Wednesday. The firm’s 50 day moving average is $70.94 and its 200 day moving average is $68.44.ALX Oncology has a 12 month low of $58.78 and a 12 month high of $117.45. While on yearly highs and lows, ALX Oncology’s today has traded high as $60.14 and has touched $58.78 on the downward trend. See More Analyst Rating at: RATING

ALX Oncology Earnings and What to expect: 

ALX Oncology last released its quarterly earnings data on August 11th, 2021. The reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.04. ALX Oncology has generated ($2.37) earnings per share over the last year (($1.61) diluted earnings per share). Earnings for ALX Oncology are expected to decrease in the coming year, from ($1.77) to ($2.38) per share. ALX Oncology has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.

Earnings for ALX Oncology are expected to decrease in the coming year, from ($1.77) to ($2.38) per share. The P/E ratio of ALX Oncology is -36.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of ALX Oncology is -36.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. ALX Oncology has a P/B Ratio of 5.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

ALX Oncology (ALXO) Moving Average Technical Analysis

5 day Moving Average is $60.99 And 5 day price change is -$9.58 (-13.97%)  with average volume for 5 day average is 161,060. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $71.59 and 20 day price change is -$19.20 (-24.56%) and average 20 day moving volume is 179,520. 50 day moving average is $70.94  and 50 day price change is -$2.52 ( -4.10%)  and with average volume for 50 days is : 260,158. 200 day moving average is $68.44  and 200 day price change is -$24.71 (-29.52%)  and with average volume for 200 days is : 236,283.

Other owners latest trading in ALX Oncology :

  • On 10/13/2021 shares held by FNY Investment Advisers LLC were 723 which equates to market value of $53K and appx 0.00% owners of ALX Oncology
  • On 9/22/2021 shares held by Nan Fung Group Holdings Ltd were 34,950 which equates to market value of $1.91M and appx 0.60% owners of ALX Oncology
  • On 9/10/2021 shares held by Jasper Ridge Partners L.P. were 25,256 which equates to market value of $1.38M and appx 0.10% owners of ALX Oncology
  • In total Institutional ownership equates to Institutional Ownership Percentage: 82.50% for ALX Oncology

See More Analyst Rating at: RATING